Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Press Briefings Press Briefing on Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19

Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19 (Moderator - Alisa Wolberg, PhD, University of North Carolina at Chapel Hill)

Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19 press release

Abstracts presented:

376 Thrombotic Microangiopathy Variants Are Independently Associated with Critical Disease in COVID-19 Patients

Eleni Gavriilaki, Panagiotis G Asteris, Styliani Kokoris, et al.

Conclusion: We have detected for the first time rare and pathogenic TMA-associated variants in patients with severe COVID-19. Our findings of variants in complement-regulatory genes and ADAMTS13 suggest genetic susceptibility and define proof-of-concept for proper selection of patients that would benefit from complement inhibition.

612 Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19


Spyridoula Vasileiou, Manik Kuvalekar, Aster Workineh, et al.

Conclusion: SARS-CoV-2 VSTs generated from convalescent individuals are Th1-polarized, polyfunctional and selectively able to kill viral antigen-expressing targets with no auto- or alloreactivity, indicative of both their selectivity and safety for clinical use. We are rapidly advancing this product to the clinic for administration in a randomized clinical trial (VSTs+SOC vs SOC) to prevent the development of severe disease in high risk hospitalized patients such as those post-transplant or therapy for hematologic malignancy.

215 Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

William A. Wood, Donna S. Neuberg, John Colton Thompson, et al.

Conclusions: Taken together, these data support the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality from COVID-19 infection. However, we see no reason, based on our data, to withhold intensive therapies from patients with underlying hematologic malignancies and favorable prognoses, if aggressive supportive care is consistent with patient preferences. Batch submissions from sites with high incidence of COVID-19 infection are ongoing. The Registry has been expanded to include non-malignant hematologic diseases, and the Registry will continue to accumulate data as a resource for the hematology community.